A Phase IIa ,Randomized, Double-blind, Placebo-controlled, Dose-exploration Study of JMKX000189 in Treatment of Moderate to Severe Active Systemic Lupus Erythematosus
Latest Information Update: 16 Oct 2023
At a glance
- Drugs JMKX-000189 (Primary)
- Indications Systemic lupus erythematosus
- Focus Therapeutic Use
- Sponsors Jemincare
Most Recent Events
- 03 Aug 2023 New trial record